Ulcerative Colitis – Access & Reimbursement – Detailed, Expanded Analysis (EU5)
MARKET OUTLOOK
The ulcerative colitis (UC) market landscape is constantly evolving. The TNF-α inhibitors have the longest tenure among all biologics for UC; however, the launch of Takeda’s Entyvio, a cell adhesion molecule (CAM) inhibitor, intensifies competition. The additional entries and expanded use of less-expensive biosimilar TNF-α inhibitors will also continue to shift market dynamics, as will the anticipated entry of the first-in-UC oral therapy (i.e., Pfizer’s Xeljanz), together with the launch of additional emerging agents with novel MOAs. All these factors will contribute to an increasingly complex market access landscape. EU5 payers and prescribers will need to carefully weigh the clinical efficacy, safety, and cost-effectiveness of each agent. As such, developers of emerging therapies looking to penetrate this market need to be wellprepared to navigate a more-complex road to access and reimbursement.
QUESTIONS ANSWERED
- What clinical and cost-related factors most strongly influence and restrict prescribing of key UC therapies? How do these differ across the EU5?
- What factors will determine the success of recently approved and emerging agents, including Xeljanz? How do payers intend to reimburse emerging agents? To what extent will payer policy impact prescribing of them?
- What can manufacturers do to achieve favorable pricing and reimbursement terms, maximize uptake, and therefore optimize market access?
PRODUCT DESCRIPTION
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
GEOGRAPHY
EU5: France, Germany, Italy, Spain, United Kingdom
PRIMARY RESEARCH
Survey of 250 gastroenterologists across the EU5 (50 per country)
Interviews with 10 EU5 payers (2 per country)
KEY DRUGS COVERED
Humira, Remicade, Simponi, Entyvio, Stelara, Inflectra/Remsima/Flixabi, Xeljanz, ozanimod, etrolizumab
CONTENT HIGHLIGHTS
- Actionable recommendations to optimize market access
- Market access success and stumbles
- Market access roadblocks
- Reimbursement dynamics
- The impact of pricing and reimbursement, policy, and coverage on prescribing
- Market access outlook for emerging therapies
Table of contents
- Ulcerative Colitis - Access & Reimbursement - Detailed, Expanded Analysis (EU5)
- Ulcerative Colitis - Access & Reimbursement - EU5
Henrique Duarte is an analyst on the Global Market Access Insights team at DRG, part of Clarivate. He is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. His focus is the EU5 and some Latin American countries. He holds a pharmaceutical science degree from the Universidade Lusófona and a postgraduate certificate in health economics from the University of York.
Andrea Kravit is the principal director of the Immune and Inflammatory Disorders team at DRG, part of Clarivate. She oversees a team of analysts and directors conducting patient-based market forecasting, market opportunity assessments, early- to late-phase pipeline analyses, and competitive analytics for the life sciences industry. Ms. Kravit holds a B.A., summa cum laude, from Boston University.
Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.
In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry
He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.